Axsome Q4 2023 net product revenue $71.5M (+193% YoY); net loss $98.7M; pipeline milestones on track

Axsome Therapeutics, Inc.

2023-FY EPS reported -$5.27 revenue$270,600,000

Total net product revenue $71.5M in Q4 2023 (+193% YoY); full year $204.9M (+309% YoY).
Auvelity net sales $49.0M in Q4 ($130.1M FY); Sunosi $22.5M Q4 ($74.8M FY, +67% YoY).
Net loss Q4 $98.7M ($2.08/share) vs $61.2M loss in Q4 2022; FY loss $239.2M ($5.27/share).
NDA submissions for AXS-07 (migraine) and AXS-14 (fibromyalgia) expected 1H 2024; SYMPHONY topline Q1 2024.
Cash $386.2M at Dec 31, 2023, up from $200.8M; sufficient to fund ops into cash flow positivity.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Axsome Therapeutics, Inc. reported the fourth quarter and full year of 2023 results: revenue $71.5 million, net income $(2.08) per share, EPS $(2.08) per share.

Period: the fourth quarter and full year of 2023
Revenue: $71.5 million
Net income: $(2.08) per share
EPS: $(2.08) per share
Result: reported results

Exact text from the filing

Total net product revenues were $71.5 million and $204.9 million for the fourth quarter and full year of 2023, representing year-over-year growth of 193% and 309%, respectively.

View on SEC.gov

Browse all earnings releases →

Axsome Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-016797

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.